Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Signed Informed Consent Form
Meet criteria for the diagnosis of allergic asthma
Be between the ages of 18 to 65 years
Have a normal chest X-ray within 2 years of screening
You may not be if
Need daily controller medication for asthma
History of hypersensitivity to the study drug or to drugs with similar chemical structures or to any ingredients, including excipients of the study medication or drugs related to omalizumab (e.g., monoclonal antibodies, polyclonal gamma globulin)
Have a documented medical history of anaphylaxis
Have lung disease other than mild allergic asthma
Have taken other investigational drugs within 30 days or 5 half-lives prior to the screening visit, whichever is longer
Are unable or unwilling to comply with study procedures and visits
Are pregnant or lactating
Have significant medical illness other than asthma, including malignancies, parasitic infections, immune system disorders, and thrombocytopenia
Have been treated with omalizumab within 12 months prior to screening
Currently smoke or have a history of smoking more than 10 pack-years
Have a history of drug or alcohol abuse, which, in the judgment of the investigator, may put the subject at risk for being unable to participate fully in the study for the duration of the study
Clareo Health | A Study of Omalizumab in the Prevention of Allergen Induced Airway Obstruction in Adults With Mild Allergic Asthma
